Last reviewed · How we verify
plerixafor GZ316455 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
plerixafor GZ316455 (plerixafor GZ316455) — Genzyme, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| plerixafor GZ316455 TARGET | plerixafor GZ316455 | Genzyme, a Sanofi Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- plerixafor GZ316455 CI watch — RSS
- plerixafor GZ316455 CI watch — Atom
- plerixafor GZ316455 CI watch — JSON
- plerixafor GZ316455 alone — RSS
Cite this brief
Drug Landscape (2026). plerixafor GZ316455 — Competitive Intelligence Brief. https://druglandscape.com/ci/plerixafor-gz316455. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing